Videos

Figlin says drugs like lenvatinib, everolimus, and cabozantinib have emerged in recent years as possible first-line therapies for RCC.

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.

Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, on the challenge of treating brain metastases in breast cancer. Anders says brain metastases generally portend a poor prognosis and treatment for them are currently scarce.

William Sikov, MD, associate director of Clinical Research, Program in Women

Matthew J. Ellis, MD, PhD, director, Sue Smith Breast Center at Baylor College of Medicine, discusses a recent study of palbociclib in primary breast cancer.

Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.

Claire Harrison, MD, discusses ruxolitinib continuing to show a benefit for patients with advanced myelofibrosis over the course of a 5 year study.

S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.

Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.

Neal Young, MD, discusses the advancement of treatment for aplastic anemia. Young said aplastic anemia used to kill almost all patients diagnosed with the disease within a year.

Jeffrey Jones, MD, discusses small molecule inhibitors of B-cell receptor signaling in chronic lymphocytic leukemia (CLL).

Amy Johnson, PhD, discusses the overall high response rates in patients with chronic lymphocytic leukemia (CLL) to a new novel bruton tyrosine kinase (BTK) inhibitor called acalabrutinib (ACP-196).

Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.

Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.

Ola Landgren, MD, PhD, on the progression treatments from combinations toward three-drug treatments and the use of monoclonal antibodies. Landgen adds that while he does have faith that monoclonal antibodies will change the treatment landscape in oncology, he says they could very well be combined with old and new drugs.

William G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.

Burtness says on average, medical professionals should take about 4 minutes or longer to properly explain the clinical trial to their patients, as well as leave ample time for questions at the end of the conversation.

David Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.

Srdan Verstovsek, MD, PhD, discusses the JAK2 inhibitor, as well as upcoming treatments like momelotinib and pacritinib, for the treatment of patients with myelofibrosis.